» Articles » PMID: 37239145

New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma

Abstract

The preoperative diagnostics of medullary thyroid carcinoma (MTC), including the measuring of the blood calcitonin level, has a number of limitations. Particular focus has recently been placed on the role of miRNAs in the development of various malignant tumors; a comparative analysis of accuracy of the existing methods for MTC diagnosis with a novel diagnosis method, evaluation of the miRNA-375 expression level, was performed in this study. The expression level of miRNA-375 in cytology samples from 555 patients with the known histological diagnosis, including 41 patients with confirmed postoperative diagnosis of MTC, was assessed. The diagnostic parameters of the basal calcitonin level, calcitonin in wash-out fluid from the FNAB needle, and miRNA-375 were compared. An assessment of the miRNA-375 expression level made it possible to detect all the MTC samples with a 100% accuracy among all the 555 cytology specimens, as well as in non-informative FNAB specimens, and specimens from the ipsilateral thyroid lobe. Parameters such as sensitivity, specificity, PPV, and NPV were 100%. The miRNA-375 level, unlike calcitonin, does not correlate with tumor volume, so it does not have the so-called "gray zone". An assessment of the miRNA-375 expression allows one to accurately distinguish MTC from other malignant and benign thyroid tumors.

Citing Articles

Could Be a Promising Marker for Preoperative Diagnosis of High-Grade Papillary Thyroid Carcinoma?.

Titov S, Kozorezova E, Lukyanov S, Sergiyko S, Demenkov P, Veryaskina Y Diagnostics (Basel). 2024; 14(23).

PMID: 39682560 PMC: 11640196. DOI: 10.3390/diagnostics14232652.


A practical nomogram for preoperatively predicting lateral cervical lymph node metastasis in medullary thyroid carcinoma: a dual-center retrospective study.

Zhu J, Guo T, Guo S, Chang L, Zhao J, Wang X Front Endocrinol (Lausanne). 2024; 15:1349853.

PMID: 39129917 PMC: 11310050. DOI: 10.3389/fendo.2024.1349853.


MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic/prognostic markers and web based tools.

Shakiba E, Boroomand S, Kheradmand Kia S, Hedayati M Oncol Res. 2024; 32(6):1011-1019.

PMID: 38827323 PMC: 11136686. DOI: 10.32604/or.2024.049235.

References
1.
Romeo P, Colombo C, Granata R, Calareso G, Gualeni A, Dugo M . Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. Endocr Relat Cancer. 2018; 25(3):217-231. DOI: 10.1530/ERC-17-0389. View

2.
Reagh J, Bullock M, Andrici J, Turchini J, Sioson L, Clarkson A . NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2. Am J Surg Pathol. 2016; 41(1):75-81. DOI: 10.1097/PAS.0000000000000740. View

3.
Ciarletto A, Narick C, Malchoff C, Massoll N, Labourier E, Haugh K . Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples. Cancer Cytopathol. 2020; 129(3):239-249. PMC: 7984450. DOI: 10.1002/cncy.22365. View

4.
Kiriakopoulos A, Giannakis P, Menenakos E . Calcitonin: current concepts and differential diagnosis. Ther Adv Endocrinol Metab. 2022; 13:20420188221099344. PMC: 9125613. DOI: 10.1177/20420188221099344. View

5.
Albores-Saavedra J, Monforte H, Nadji M, Morales A . C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988; 19(7):795-9. DOI: 10.1016/s0046-8177(88)80262-4. View